ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

Maintenance treatment in multiple myeloma: A new era

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia

Background of the KEYLYNK-007 trial for advanced solid tumours

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma